Alexander B. Radaoui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alexander B. Radaoui has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Delaidelli
Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada
41 shared publications - Amal M. El-Naggar
Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, Canada
41 shared publications - Amber K. Weiner
Children's Hospital of Philadelphia
41 shared publications - Amy Li
Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada
41 shared publications - Brian Mooney
Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada; Department of Basic and Translational Research, BC Cancer Research Institute, Vancouver, BC, Canada
41 shared publications - Christopher S. Hughes
Canada's Michael Smith Genome Sciences Centre , British Columbia Cancer Agency , Vancouver , British Columbia V5Z 1L3 , Canada
41 shared publications
Latest Publications
- 24 July 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (6)
Setting expectations: The influence of pubic diastasis and surgical burden in isolated female epispadias
- 24 July 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (6)
Setting expectations: The influence of pubic diastasis and surgical burden in isolated female epispadias
- 18 February 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (3) , 105811
Pubic diastasis as a predictor of continence outcomes in the isolated male epispadias patient: An innovative prognostic factor
- 18 February 2026
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 22 (3) , 105811
Pubic diastasis as a predictor of continence outcomes in the isolated male epispadias patient: An innovative prognostic factor
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Expression of ATP11C, SLCO5A1, and STEAP2 in publicly available datasets.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Expression of ATP11C, SLCO5A1, and STEAP2 in publicly available datasets.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Domain structure of ENPP1 and CDH11.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Domain structure of ENPP1 and CDH11.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
CDH11 is a surface protein in EwS
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
CDH11 is a surface protein in EwS
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S4 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Relative abundance values for proteins identified by proteomics.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S4 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Relative abundance values for proteins identified by proteomics.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Consensus clustering of proteomics data.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Consensus clustering of proteomics data.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
ENPP1 is expressed at higher levels in non-metastatic EwS vs metastatic EwS.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
ENPP1 is expressed at higher levels in non-metastatic EwS vs metastatic EwS.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Log2 fold change values for proteins in EwS xenografts vs SuperMix.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
Log2 fold change values for proteins in EwS xenografts vs SuperMix.
- Open Access
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
ENPP1 and CDH11 have high EwS dependency.
- 1 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Surface and Global Proteome Analyses Identify ENPP1 and Other Surface Proteins as Actionable Immunotherapeutic Targets in Ewing Sarcoma
ENPP1 and CDH11 have high EwS dependency.